In a pilot study of cyclical chemotherapy in patients with poor-prognosis non-Hodgkin's lymphoma (NHL), high-dose methotrexate (MTX) 1 g/m2 with folinic acid rescue was given as initial treatment and then between cycles of a single-arm CHOP combination administered every 4 weeks. Of 21 patients with previously untreated or minimally treated grade 2 (high-grade) histology stage II/III/IV NHL, 13 (62%) achieved complete remission (CR); the CR rate for stage III/IV patients was 56%. Of all 25 patients with grade 2 stage II/III/IV NHL, including previously treated patients, 16 (64%) achieved CR. The median folow-up of patients who completed treatment is currently 22 months and only 1 relapse has been recorded in the CR group. Only five of 24 grade 2 patients given the initial ‘test’ MTX failed to show any response, and eight patients achieved partial remission (PR) as a result of this single treatment. The response to MTX-CHOP in nine patients with grade 1 (low-grade) histology NHL was poor; only two achieved CR. These findings lend support to other data which indicate a useful role for MTX in the induction chemotherapy of advanced high-grade NHL, though the optimum dosage and drug sequence have yet to be determined.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Blackledge G, Bush H, Chang J, et al. (1980) Intensive combination chemotherapy with vincristine, Adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. Eur J Chancer 16:1459
Canellos GP, Lister TA, Skarin AT (1978) Chemotherapy of the non-Hodgkin's lymphomas. Cancer 42:932
Canellos GP, Skarin AT, Rosenthal DS, Maloney WC, Frei E (1981) Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavourable histology. Cancer Treat Rep [Suppl 1] 65:125
Canellos GP, Skarin AT, Rosenthal DS, et al. (1982) High-dose methotrexate combination chemotherapy (M-BACOD) of advanced favourable and intermediate prognosis histology non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1:159
Crowther C (1981) New approaches to the management of patients with non-Hodgkin's lymphoma of high-grade pathology. Br J Cancer 43:417
De Vita VT, Canellos GP, Chabner B, Schein PS, Hubbard SP, Young RC (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy. Lancet I:248
Fisher RI, De Vita VT, Johnson BL, Sumon R, Young RC (1977) Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 63:177
Gomez GA, Stutzman L, Moayeri H, et al. (1982) Combination of methotrexate (COP or CHOP) in the treatment of previously untreated and treated lymphomas. Cancer Treat Rep 66:43
Henry K, Bennett MH, Farrer-Brown G (1978) Classification of the non-Hodgkin's lymphomas. In: Anthony PR, Woolf N (eds) Recent advances in histopathology, vol 10. Churchill Livingstone, Edinburgh London New York, p 275
Lister TA, Cullen MH, Brearley RG, et al. (1978) Combination chemotherapy for advanced Hodgkin's lymphoma of unfavourable histology. Cancer Chemother Pharmacol 1:107
McKelvey EM, Gottlieb JA, Wilson HE, et al. (1976) Hydroxydaunorubicin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484
Pettingale KW (1981) The management of generalised grade 2 non-Hodgkin's lymphomas. (Report No. 18) Clin Radiol 32:553
Schein PS, De Vita VT, Hubbard S, et al. (1976) Bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisolone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 85:417
Skarin AT, Rosenthal DS, Maloney WC, Frei E III (1977a) Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisolone (BACOP). Blood 49:759
Skarin AT, Zuckerman KS, Pitman SW, et al. (1977b) High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin's lymphoma including CNS involvement. Blood 50:1039
Skarin AT, Canellos GP, Rosenthal D, Case D, Maloney W, Frei E III (1980) Therapy of diffuse histiocytic (DH) and undifferentiated (DU) lymphoma with high-dose methotrexate and citrovorum factor rescue (MTX-CF), bleomycin (B), Adriamycin (A), cyclophosphamide (C), Oncovin (O) and Decadron (D). (M-BACOD). Proc Am Soc Clin Oncol 21:463
Skarin AT, Canellos GP, Rosenthal DS, et al. (1983) Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (in press)
Sweet DL, Colomb HM, Ultmann JE, et al. (1980) Cyclophosphamide, vincristine, methotrexate with Leucovorin rescue, and Cytarabine (COMLA) combination for advanced diffuse histiocytic lymphoma. Ann Intern Med 92:785
Sweet DL, Collins RD, Stein RS, Ultmann JE (1982) Prognostic significance of the Lukes and Collins classification in patients treated with COMLA. Cancer Treat Rep 66:1107
for the Yorkshire Lymphoma Group (YLG)
About this article
Cite this article
Child, J.A., Barnard, D.L., Cartwright, S.C. et al. A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL). Cancer Chemother. Pharmacol. 11, 153–158 (1983). https://doi.org/10.1007/BF00254195
- Pilot Study
- Complete Remission
- Initial Treatment